Submitted: 12 April 2013
Accepted: 12 April 2013
Published: 1 December 2012
Abstract Views: 8774
PDF: 1900
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Gout is a metabolic disorder caused by hyperuricemia resulting in joints and other tissues deposition of urate crystals. Clinical manifestation includes recurrent attacks of arthritis and accumulation of crystalline deposits called tophi. Gout is considered a progressive disease that, without long-term treatment, can progress to severe tophaceous gout. The disease is increasing in prevalence as a result of changes in diet, lifestyle and environmental factors. Hyperuricemia has a fundamental role as risk factor in the development of gout and seems also to be a risk factor for some comorbidities. The goal of the treatment of gout is to reduce serum uric acid levels sufficiently that crystals can no longer form. A future research agenda should include the identification of genes associated with risk for gout and the development of new urate lowering drugs with a specific target. In the next future, controlled studies are also required to understand the significance and the underlying mechanism of the association between hyperuricemia and some comorbidities.

Marcolongo, R. (2012). GOUT: THE KING OF DISEASES AND THE DISEASE OF KINGS. Journal of the Siena Academy of Sciences, 4(1), 7–17. https://doi.org/10.4081/jsas.2012.1561


Download data is not yet available.